
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is a biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH), leveraging significant research partnerships with AbbVie and BI to derive most of its revenue. The company's lead product candidate, lanifibranor, has shown promising clinical results, including a 42% improvement in fibrosis compared to a 24% improvement with placebo, marking it as a potential best-in-class therapy in the NASH landscape. Management's positive outlook is reinforced by the candidate's ability to target both MASH resolution and fibrosis improvement, suggesting strong market adoption potential, particularly among patients who are non-responsive to existing therapies.
Bears say
Inventiva SA is facing a challenging financial outlook primarily due to a significant net loss of €175.9 million, or €1.62 per share, highlighting the company's ongoing financial struggles. The main clinical program, lanifibranor, is currently in Phase III development, and any issues related to efficacy or safety discovered in these early stages could severely impact the company's stock performance. Additionally, the risks associated with clinical trial failures, regulatory delays, and potential difficulties in accessing equity capital markets further exacerbate the uncertainties surrounding Inventiva's operational and financial stability.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares